Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Vineyard

Foot and Ankle Surgery Dallas, TX Medical Doctor

NPI 1376723940 CMS profile 289617

9301 N Central Expy, Suite 400, Dallas, TX 75231

Open in the dashboard

General payments

$5,949

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Vineyard of Dallas, TX is reported in the CMS Open Payments database as having received $5,949 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $645 25
2024 General $1,426 28
2023 General $212 8
2022 General $1,539 11
2021 General $1,565 14
2020 General $223 8
2019 General $340 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Vineyard
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Joseph Vineyard were reported at $645. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Joseph Vineyard Foot and Ankle Surgery median Middle half National median
2019 $340 $1,327 $279–$5,421 $163
2020 $223 $795 $121–$3,473 $114
2021 $1,565 $1,289 $201–$4,963 $132
2022 $1,539 $1,539 $270–$6,067 $149
2023 $212 $1,117 $257–$5,264 $160
2024 $1,426 $1,064 $235–$4,944 $164
2025 $645 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $1,938 19 payments
  2. Pylant Medical $1,788 10 payments
  3. Smith+Nephew, Inc. $829 30 payments
  4. Stryker Corporation $353 14 payments
  5. Integra LifeSciences Corporation $284 10 payments
  6. restor3d, inc. $207 1 payment
  7. Bioventus LLC $202 6 payments
  8. Wright Medical Technology, Inc. $122 7 payments
  9. Avanos Medical $63 2 payments
  10. Treace Medical Concepts, Inc. $63 4 payments
  11. Other $100 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,122 105 payments
  2. Education $2,400 2 payments
  3. Travel and Lodging $427 1 payment
Products named General payments · program years 2019–2025
  1. PANTA NAIL $264 9 payments
  2. HALLU-LOCK $264 9 payments
  3. TOTAL FOOT SYSTEM $264 9 payments
  4. CADENCE ANKLE REPLACEMENT SYSTEM $264 9 payments
  5. SALTO TALARIS TOTAL ANKLE PROSTHESIS $264 9 payments
  6. Cadence $209 8 payments
  7. EXOGEN ULTRASOUND BONE HEALING SYSTEM $178 5 payments
  8. EVOS $166 6 payments
  9. HAT-TRICK $142 6 payments
  10. Panta 2 $134 1 payment
  11. Other $982 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

254

Median for Orthopedic Surgery: 203

Drug cost

$1,972

Median for Orthopedic Surgery: $1,433

Branded share of claims

71.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 96 $783
Ondansetron Odt Ondansetron Brand 71 $589
Methylprednisolone Generic 32 $192
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $161
Meloxicam Generic 27 $148
Gabapentin Generic 13 $101

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$174,946

Of which drugs: $2,657

Medicare patients

617

Average age 74

Services billed

3,295

421 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Ischemic heart disease 23%
Depression 23%
Osteoporosis 19%
Atrial fibrillation 15%
Cancer 15%
Diabetes 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 112 770 $565

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record